Skip to main content

Agrify Announces Results for FY2022 and First Quarter 2023

TROY, Mich., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Agrify Corporation (Nasdaq: AGFY) (“Agrify” or the “Company”), a leading provider of innovative cultivation and extraction solutions for the cannabis industry, today announced financial results for the fiscal year ended December 31, 2022 (“FY 2022”), and for the first quarter ended March 31, 2023 (“Q1 2023”).

“In 2023, we continued to make progress on our turn-around,” said Raymond Chang, Chairman and Chief Executive Officer of Agrify. “After a difficult FY 2022, we have reexamined our business model, explored our strategic options, and reevaluated our product offerings to better serve our customers. In terms of the strategic changes, our top priorities have been: (1) restructuring our debts; (2) reducing our costs and headcount; (3) improving our product offerings; and (4) getting some of our key products CE-certified for the international markets. We believe that we have made strong progress in all four of these areas and will continue to prioritize these efforts. The historical acquisitions of the four extraction companies continue to add value, as the combination of Agrify, Precision Extraction Solutions, Pure Pressure, Lab Society, and Cascade Sciences allows us to offer a comprehensive portfolio of cultivation and extraction technologies to our customers. Now that the four acquired companies are completely integrated into Agrify, we believe the synergies are showing and will become even more robust in 2024.”

First Quarter 2023 Financial Results Summary

  • Revenue was $5.8 million for Q1 2023, compared to $26.0 million for the first quarter of 2022 (“Q1 2022”).
  • Gross profit for Q1 2023 was $1.0 million, compared to $4.2 million in Q1 2022.
  • Operating expenses were $8.6 million for Q1 2023, compared to $13.9 million in Q1 2022. The decrease was largely due to a decrease in general and administrative costs.
  • Operating loss for Q1 2023 was $7.6 million, compared to $9.8 million for Q1 2022.
  • Net loss attributable to Agrify for Q1 2023 was $10.3 million, or $9.63 per diluted share, compared to net income of $1.8 million, or $13.79 per diluted share for Q1 2022.

Fiscal Year 2022 Financial Results Summary

  • Revenue was $58.3 million for FY 2022, a decrease of 2.7% compared to $59.9 million for the fiscal year ended December 31, 2021 (“FY 2021”).
  • Gross profit for FY 2022 was a loss of $31.8 million, compared to a profit of $5.2 million in FY 2021.
  • Operating expenses were $161.5 million for FY 2022, compared to $40.3 million in FY 2021. The increase in operating expenses is largely attributable to $69.9 million of impaired goodwill and $39.0 million of bad debt expenses.
  • Operating loss for FY 2022 was $193.3 million, compared to $35.1 million for FY 2021.
  • Net loss attributable to Agrify for FY 2022 was $188.2 million, or $902.19 per share, compared to a net loss of $32.5 million, or $340.75 per share, for FY 2021.

Recent Business Highlights:

Extraction Division

Agrify launched the Cannabeast 13 Distillation System – the Cannabeast 13 Thin Film Distillation System transitioned from its initial sale to SkyMint in 2022 to an official production launch in Q1 2023. Notably, this technology gained traction with three sales to major Multi-State Operators (MSOs), including Trulieve, Ascend Wellness, and MariMed, underscoring its growing appeal within the industry. The Cannabeast 13 offers 1-8 liters per hour input feed capability designed solely around distilling high boiling point compounds coupled with low boiling point constituents in feed stock to streamline and maximize throughput.

In addition, Agrify launched the PX30 Hydrocarbon Extraction System, the largest member of the PX Series. The PX30 has a 30 pound capacity and a runtime of less than 60 minutes, making it one of the largest and fastest extractors on the market. This robust system is poised to offer enhanced capabilities for hydrocarbon extraction, catering to the demands of commercial operators focusing on large-scale batch processing and extracting for creating direct-to-consumer cannabis products.

Lastly, Agrify made significant strides to receive UL Compliance for EXP Rooms. All of Precision Extraction Solutions’ EXP Rooms, including the EXP1 and EXP2, meet UL standards. These rooms are the ideal choice for C1D1 environments, emphasizing Precision Extraction Solutions’ commitment to safety and quality within cannabis extraction facilities. 

These industry developments illustrate the continuous innovation, and commitment to safety within the cannabis sector as our company adapts to evolving market demands. 

Cultivation Division

Agrify’s newly commercialized customer, Nevada Holistic Medicine (“NHM”), located just off of the Las Vegas strip, is already seeing consistent and successful average harvests of 9 pounds of A-grade flower per Vertical Farming Unit (“VFU”), or roughly 64 grams per canopy square foot. The NHM team is seeing 90%+ A-grade flower being produced with exceptional color, trichome, and terpene levels.

Agrify has successfully assisted another cultivation facility, Denver Greens LLC, to reach commercialization with 60 VFUs to produce high-quality cannabis products in Colorado. Denver Greens recently entered a distribution agreement with Kush Masters, a family run and operated supplier of high-quality cannabis products in Colorado, with a reputation of providing products and services since 2014. Under this distribution agreement, some of Denver Greens’ VFU-grown cannabis is expected to be available on the market as pre-rolled joints and flower in approximately 350 Colorado dispensaries.

In addition, Agrify is pleased to announce the signing of two new customers, Golden Lake Business Park, located in California, and Harvest Works, located in New Jersey, with both facilities expected to begin commercialization in 2024.

About Agrify (Nasdaq: AGFY)

Agrify is a leading provider of innovative cultivation and extraction solutions for the cannabis industry, bringing data, science, and technology to the forefront of the market. Our proprietary micro-environment-controlled VFUs enable cultivators to produce the highest quality products with unmatched consistency, yield, and ROI at scale. Our comprehensive extraction product line, which includes hydrocarbon, ethanol, solventless, post-processing, and lab equipment, empowers producers to maximize the quantity and quality of extract required for premium concentrates. For more information, please visit Agrify at

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning Agrify and other matters. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements including, without limitation, statements regarding future financial results, including expected revenue, integration of prior acquisitions, the timing and ability to launch new products, potential cost savings realized from reducing costs, expected long-term growth in the cannabis industry, the ability to realize revenue from bookings, backlog, pipeline, and specific transactions described herein, including the agreements with Denver Greens and Nevada Holistic Medicine, Golden Lake Business Park, and Harvest Works, project timelines, commercialization timelines for Agrify’s VFU customers, and Agrify’s ability to deliver solutions and services. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. You should carefully consider the risks and uncertainties that affect our business, including those described in our filings with the Securities and Exchange Commission (“SEC”), including under the caption “Risk Factors” in our Annual Report on Form 10-K to be filed for the year ended December 31, 2022 with the SEC, which you will be able to obtain on the SEC website at These forward-looking statements speak only as of the date of this communication. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements, whether as a result of any new information, future events, or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our public announcements and filings with the SEC.

Consolidated Statements of Operations
(In thousands, except share and per share amounts)

  Three Months Ended
March 31,
  Years Ended
December 31,
  2023  2022  2022  2021 
Revenue $5,804  $26,021  $58,259  $59,859 
Cost of goods sold  4,816   21,851   90,054   54,625 
Gross (loss) profit  988   4,170   (31,795)  5,234 
General and administrative  6,931   9,759   73,354   30,807 
Selling and marketing  1,590   2,090   9,338   4,163 
Research and development  735   2,084   8,179   3,925 
Change in contingent consideration  (684)     (2,156)  1,412 
Impairment of property and equipment        2,912    
Impairment of goodwill and intangible assets        69,904    
Total operating expenses  8,572   13,933   161,531   40,307 
Loss from operations  (7,584)  (9,763)  (193,326)  (35,073)
Interest (expense) income, net  (799)  559   (8,750)  74 
Other income (expense)  4      1,316   (31)
Change in fair value of warrant liabilities  2,672   10,785   51,461    
Gain on forgiveness of PPP loan           45 
(Loss) gain on extinguishment of notes payable  (4,620)     (38,985)  2,685 
Other income (expense), net  (2,743)  11,344   5,042   2,773 
Net (loss) income before income taxes  (10,327)  1,581   (188,284)  (32,300)
Income tax benefit (expense)     200   (23)  (25)
Net (loss) income  (10,327)  1,781   (188,307)  (32,325)
(Income) loss attributable to non-controlling interests     (1)  134   (140)
Net loss attributable to Agrify $(10,327) $1,780  $(188,173) $(32,465)
Net loss per share attributable to Common                
Stockholders – basic (1) $(9.63) $14.48  $(902.19) $(340.75)
Net loss per share attributable to Common                
Stockholders – diluted (1) $(9.63) $13.79  $(902.19) $(340.75)
Weighted average commons shares                
outstanding – basic (1)  1,072,292   122,946   208,573   95,455 
Weighted average commons shares                
outstanding – diluted (1)  1,072,292   129,045   208,573   95,455 

(1)Periods presented have been adjusted to reflect the 1-for-10 reverse stock split on October 18, 2022, and the 1-for-20 reverse stock split on July 5, 2023.

Consolidated Balance Sheets
(In thousands)

  March 31,  December 31, 
  2023  2022 
Assets (unaudited)    
Cash and cash equivalents $1,476  $10,457 
Restricted cash     10,000 
Marketable securities  14   460 
Accounts receivable, net  1,197   1,070 
Inventory, net  19,995   21,396 
Prepaid expenses and other current assets  2,990   1,510 
Total current assets  25,672   44,893 
Loans receivable, net  12,806   12,214 
Property and equipment, net  9,658   10,044 
Right-of-use assets, net  2,343   2,210 
Other non-current assets  153   326 
Total assets $50,632  $69,687 
Accounts payable $21,128  $20,543 
Accrued expenses and other current liabilities  12,636   16,380 
Operating lease liabilities, current  798   734 
Long-term debt, current  2,084   28,833 
Deferred revenue  3,239   4,112 
Total current liabilities  39,885   70,602 
Warrant liabilities  3,313   5,985 
Operating lease liabilities, net of current  1,707   1,587 
Long-term debt, net of current  22,554   407 
Other non-current liabilities  112   147 
Total liabilities  67,571   78,728 
Stockholders’ Equity        
Common stock (1)  1   1 
Additional paid-in capital  240,304   237,875 
Accumulated deficit  (257,475)  (247,148)
Total stockholders deficit  (17,170)  (9,272)
Non-controlling interests  231   231 
Total liabilities and stockholders’ equity $50,632  $69,687 

(1)Periods presented have been adjusted to reflect the 1-for-10 reverse stock split on October 18, 2022, and the 1-for-20 reverse stock split on July 5, 2023.

Condensed Consolidated Cash Flows Data
(In thousands)

  3 Months ended 
  March 31,  March 31, 
  2023  2022 
Cash flows (used in) provided by: (unaudited)    
Operating activities $(9,469) $(30,875)
Investing activities  9,795   (13,365)
Financing activities  (9,307)  87,431 
Net (decrease) increase in cash and cash equivalents $(8,981) $43,191 

  12 Months ended 
  Dec 31,  Dec 31, 
  2022  2021 
Cash flows (used in) provided by:      
Operating activities $(72,021) $(30,149)
Investing activities  (2,317)  (104,740)
Financing activities  72,781   138,792 
Net (decrease) increase in cash and cash equivalents $(1,557) $3,903 

Non-GAAP Financial Measures

To supplement our financial information presented in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, we use Adjusted EBITDA, which is a non-U.S. GAAP financial measure to clarify and enhance an understanding of past performance. We believe that the presentation of Adjusted EBITDA enhances an investor’s understanding of our financial performance. We further believe that Adjusted EBITDA is a useful financial metric to assess our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business. We use certain financial measures for business planning purposes, measuring our performance relative to that of our competitors and determining our compliance with certain debt instruments. We utilize Adjusted EBITDA as a key measure of our performance.

We calculate Adjusted EBITDA as net loss adjusted to exclude (i) tax provision and benefit; (ii) interest income and expense, net; (iii) other income and expense, net; (iv) depreciation and amortization; (v) stock-based compensation expense; (vi) acquisition-related expenses; (vii) investment banker termination fees; (viii) restructuring charges; (ix) impairments to long-lived assets; (x) gains and losses associated with the extinguishment of debt; (xi) changes in the fair value of warrant liabilities; (xii) changes in contingent consideration; (xiii) legal settlement charges; and (xiv) other items affecting our results that we do not view as representative of our ongoing operations, including losses associated with write-offs.

We believe Adjusted EBITDA is commonly used by investors to evaluate our performance and that of our competitors. However, our use of the term Adjusted EBITDA may vary from that of others in our industry. Adjusted EBITDA should not be considered as an alternative to net loss before taxes, net loss, loss per share or any other performance measures derived in accordance with U.S. GAAP as measures of performance.

Adjusted EBITDA has important limitations as an analytical tool and you should not consider it in isolation or as a substitute for analysis of our results as reported under U.S. GAAP. Some of the limitations of Adjusted EBITDA include (i) Adjusted EBITDA does not properly reflect capital commitments to be paid in the future, and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures. Our public offering and acquisition-related expenses, including legal, accounting, and other professional expenses, reflect cash expenditures and we expect such expenditures to recur from time-to-time. Our Adjusted EBITDA may not be comparable to similarly titled measures of other companies because they may not calculate Adjusted EBITDA in the same manner as we calculate the measure, limiting its usefulness as a comparative measure.

In evaluating Adjusted EBITDA, you should be aware that in the future we will incur expenses similar to the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by these expenses or any unusual or non-recurring items. Adjusted EBITDA should not be considered as an alternative to loss before benefit from income taxes, net loss, earnings per share, or any other performance measures derived in accordance with U.S. GAAP. When evaluating our performance, you should consider Adjusted EBITDA alongside other financial performance measures, including our net loss and other GAAP results.

The following table presents a reconciliation of Adjusted EBITDA from the most comparable GAAP measure, net loss, for the three--month periods ended March 31, 2023 and 2022 and the fiscal years ended December 31, 2022 and 2021, respectively:

Reconciliation of GAAP Net Income (Loss) Attributable to Agrify Corporation to
Non-GAAP Adjusted EBITDA
(In thousands)

  Three Months Ended
March 31,
  Years Ended
December 31,
  2023  2022  2022  2021 
Net income (loss) attributable to Agrify Corporation $(10,327) $1,780  $(188,173) $(32,465)
Income tax (benefit) expense     (200)  23   25 
Interest expense (income)  799   (559)  8,750   (74)
Other (income) expense  (4)     (1,316)  31 
Depreciation and amortization  445   1,052   3,047   1,310 
Stock-based compensation  859   953   4,319   5,552 
Investment banker termination fees     637      2,400 
Acquisition- related expenses     637   2,251   4,559 
Restructuring charges     387   2,262    
Impairment charges        72,816    
Loss (gain) on debt extinguishment  4,620      38,985   (2,685)
Change in fair value of warrant liabilities  (2,672)  (10,785)  (51,461)   
Change in contingent consideration  (684)     (2,156)  1,412 
Gain on forgiveness of PPP loan           (45)
Legal settlement        (36)   
Adjusted EBITDA $(6,964) $(6,098) $(110,689) $(19,980)

Company Contacts 

Agrify Investor Relations
(857) 256-8110 

Primary Logo

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.